Severe inflammation weakens the body’s ability to kill cancerous blood cells in people with acute myeloid leukemia, a study shows.
Afami-cel (afamitresgene autoleucel; formerly ADP-A2M4), an adoptive T-cell receptor therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a phase I clinical trial led by researchers at MD Anderson Cancer Center.
Results from the first completed clinical trial facilitated and organized by DKMS, the world’s largest stem cell donor center, suggest that adult patients who have relapsed or refractory acute myeloid leukemia should receive stem cell transplantation as soon as possible.
A large study found that expanded Medicaid coverage under the Affordable Care Act leads to better survival outcomes for young adults ages 18-39 newly diagnosed with cancer, particularly those who identified as Hispanic or non-Hispanic Black.
A global, phase III clinical trial evaluating the safety and efficacy of TAVT-45 (abiraterone acetate) granules for oral suspension, an investigational enhanced formulation of abiraterone acetate for the treatment of metastatic prostate cancer, produced positive topline results.
HERIZON-BTC-01, a pivotal phase IIb, open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in patients with previously treated HER2-amplified and expressing biliary tract cancers, produced positive topline results.
A regimen including oral paclitaxel plus Athenex (encequidar) in combination with a PD-1 inhibitor and carboplatin showed positive results in triple-negative, high-risk, early-stage breast cancer. The oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia.
A team from 15 U.S. medical centers led by UT Southwestern Simmons Cancer Center researchers performed the first analysis of Jelmyto (UGN-101) to treat upper urinary tract urothelial cancers.
UT Southwestern immunologists have uncovered a key pathogenic event prompted by obesity that can trigger severe forms of nonalcoholic fatty liver disease and potential liver failure. The finding, published in Immunity, could pave the way for developing therapies to treat nonalcoholic steatohepatitis.
Interim results from the ongoing OPTIMIZE-1 phase II study of mitazalimab in combination with chemotherapy, mFOLFIRINOX, in first line metastatic pancreatic cancer demonstrate an objective response rate of 52% in 23 evaluable patients, as per the Response Evaluation Criteria in Solid Tumors.
